Formulation considerations and applications of solid lipid nanoparticles

American Pharmaceutical Review

Volumn 16, Issue 1, 2013, Pages

  Grana, Anne ^a   Limpach, Aimee ^a   Chauhan, Harsh ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BETAMETHASONE VALERATE; EMODIN; FLUOROURACIL; NANOCAPSULE; SOLID LIPID NANOPARTICLE; TEMOZOLOMIDE; TETRANDRINE;

ARTICLE; BIODEGRADABILITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; GEL; HUMAN; LIPOPHILICITY; MELTING POINT; MICROEMULSION; NONHUMAN; PARKINSON DISEASE; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; ULTRAVIOLET RADIATION; WATER CONTENT; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 84874878824     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007;2:16-16.
2. Fanun M, Dash AK, Singh S. Colloids in drug delivery. Vol 148. Boca Raton, FL: CRC Press/ Taylor & Francis; 2010.
3. Gelperina SF, Kisich K, Michael,D., FAU IM, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. American journal of respiratory and critical care medicine 2005 JID -9421642. 0223(1073-449; 1073-449).
4. Pardeike J, Hommoss A, Müller R,H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1-2):170- 184.
5. Uner MF, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. International journal of nanomedicine 2007 JID -101263847. 1218.
6. Zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism. European Journal of Pharmaceutics and Biopharmaceutics. 1998;45(2):149-155.
7. Wang S, Chen T, Chen R, Hu Y, Chen M, Wang Y. Emodin loaded solid lipid nanoparticles: Preparation, characterization and antitumor activity studies. Int J Pharm. 2012;430(1-2):238-246.
8. Jensen LB, Magnussson E, Gunnarsson L, Vermehren C, Nielsen HM, Petersson K. Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles. Int J Pharm. 2010;390(1):53-60.
9. Müller,R.H., Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery -a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
10. Du B, Yan Y, Li Y, Wang S, Zhang Z. Preparation and passive target of 5-fluorouracil solid lipid nanoparticles. Pharm Dev Technol. 2010;15(4):346-353.
11. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257-1272.
12. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3):165-196.
13. Li S, Ji Z, Zou M, Nie X, Shi Y, Cheng G. Preparation, characterization, pharmacokinetics and tissue distribution of solid lipid nanoparticles loaded with tetrandrine. AAPS PharmSciTech. 2011;12(3):1011-1018.
14. Saupe A, Wissing SA, Lenk A, Schmidt C, Müller R,H. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) -structural investigations on two different carrier systems. Biomed Mater Eng. 2005;15(5):393-402.
15. Pardeike J, Hommoss A, Müller R,H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1-2):170- 184.
16. Mitri K, Shegokar R, Gohla S, Anselmi C, Müller R,H. Lipid nanocarriers for dermal delivery of lutein: Preparation, characterization, stability and performance. Int J Pharm. 2011;414(1-2):267-275.
17. Huang G, Zhang N, Bi X, Dou M. Solid lipid nanoparticles of temozolomide: Potential reduction of cardial and nephric toxicity. Int J Pharm. 2008;355(1-2):314-320.
18. Esposito E, Fantin M, Marti M, et al. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res. 2008;25(7):1521-1530.